We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-8.50 | -0.48% | 1,775.00 | 1,771.00 | 1,771.50 | 1,779.00 | 1,764.50 | 1,773.50 | 9,685,415 | 16:35:19 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.80 | 72.91B |
Date | Subject | Author | Discuss |
---|---|---|---|
25/10/2017 09:46 | Well, my NHS (Wales) shingles jab was Zostavax by Sanofi. Sorry ! | zingaro | |
23/10/2017 17:59 | 2hog - I will ask on Wednesday when I get mine. | zingaro | |
23/10/2017 17:43 | Is that shingles drug the one that the nhs uses now,you have to be 70 to get it as I enquired recently?? | 2hoggy | |
23/10/2017 16:17 | GSK should definitely be looking at buying Immupharma's lupus drug Lupuzor which finishes Phase 3 in Jan 2018 and seems set to wipe out GSKs lupus drug Benlysta on price, efficacy and safety. | city chappy | |
23/10/2017 13:35 | NICE nod for GSK’s ‘bubble baby syndrome’ gene therapy | philanderer | |
20/10/2017 23:56 | Nice :-) “We are absolutely thrilled to get to this point because the science behind this vaccine offers tremendous potential for helping patients, protecting them against getting shingles and its complications,&rdquo GSK has been keenly awaiting the FDA’s ruling, eager to get to market a vaccine analysts estimate could reach $1 billion a year in sales by 2022 | philanderer | |
20/10/2017 23:51 | Shingrix approved by FDA | romeike | |
20/10/2017 17:08 | I own 30% of these myself. Oops no, got the decimals wrong it should be .03%, or maybe .003% | jadeticl3 | |
20/10/2017 15:53 | Thanks, anhar ... that explains it nicely! | tradermichael | |
20/10/2017 15:35 | The explanation for the ostensibly very low institutional holdings is that the evidence presented covers only US inst. holders who are only a small minority of the total inst. holders since GSK is a Brit company. So that report is worthless for identifying the overall level of institutional trading in GSK shares and therefore useless for drawing any conclusions from it. Not that knowing inst. trading is of any use anyway as a guide to the merits of the shares. | anhar | |
20/10/2017 14:31 | GSK will announce their third quarter 2017 results on Wednesday 25 October at 12pm BST (7am EST) - you can register for the webcast on | tradermichael | |
20/10/2017 12:45 | ...must be! | alphorn | |
20/10/2017 11:56 | Blackrock alone holds 6.66%. There is a typo, obviously. | grahamite2 | |
20/10/2017 11:51 | So little private investors own 90%+ of glaxo !! Something very wrong there! | mattboxy | |
20/10/2017 11:36 | The figures are as reported in the last quarter's SEC 13F filings | tradermichael | |
20/10/2017 11:31 | Institutions own 09.34% of GlaxoSmithKline plc (GSK)’s shares. I find that very hard to believe. Surely something like 69.34% or 79.34% is more likely? | grahamite2 | |
20/10/2017 09:05 | There are a lot of automated websites about giving the sort of info above. I find it makes it harder to get proper news. Many seem to describe the daily share price movements..I wonder how they make money | dr biotech | |
20/10/2017 09:01 | Never had the jab .... never had 'flu. Anyway, Recent insider trends for GlaxoSmithKline plc (NYSE:GSK) have caught the attention of investors. Patters in insider activity can help analysts formulate an outlook for a stock. In the case of GSK, the data has a lot to say about how the stock might perform going forward. Institutions own 09.34% of GlaxoSmithKline plc (GSK)’s shares. The total value of these holdings, in millions, is $9,389. Among active positions in the latest quarter, 343 holders increased their positions by a total of 22.86 million shares, 332 holders decreased the positions by a total of 14.11 million shares, and 161 holders held their positions. This works out to a net increase in ownership of 8.74 million shares, and suggests that institutions are feeling bullish about the stock. Among new and sold out positions, 64 holders initiated new positions by a total of 2.82 million shares and 62 holders exited their positions by a total of 1.4 million shares. This nets out to an increase of 1.41 million shares and is a bullish sign for GSK. | tradermichael | |
19/10/2017 19:14 | Had the jab every year for six years, not had flu since | romeike | |
19/10/2017 16:13 | Heading to test 1550p, then onwards & upwards | ny boy | |
19/10/2017 12:37 | Had the flu jab. Hoping the outlook this winter is better than some anticipate. NHS workers now need to sign a form giving reasons, if they refuse vaccination. | essentialinvestor | |
19/10/2017 08:16 | LONDON (Alliance News) - GlaxoSmithKline PLC said Wednesday that the World Health Organization has awarded pre-qualification for a new four-dose vial version of its Synflorix vaccine for pneumococcal disease in infants and children. This pre-qualification is mainly for countries that receive support from Gavi, an organisation that seeks to improve access to vaccines for children in, and is aimed at ensuring that vaccines secured through UNICEF for national immunization in low and middle income countries are appropriately safe and effective. This follows on from a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use. The formulation of the vaccine has been developed to specifically address cold-chain and storage challenges faced in some areas of the world, Glaxo said. "Today's WHO pre-qualification for our Synflorix four-dose vial is an important step in helping to ensure children under the age of five in developing countries are protected against this deadly disease. Since 2009, we have delivered more than 500 million doses of this critical pneumococcal vaccine. Through this presentation, we are committed to expanding access to children in Gavi countries where the need is greatest," said Glaxo Vaccines Chief Medical Officer Thomas Breuer. | tradermichael | |
18/10/2017 13:54 | 'GSK, Plasticell sign deal to produce haematopoietic cells' | philanderer | |
18/10/2017 08:37 | Shingrix will reach blockbuster status by 2022....... ;0) | tradermichael |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions